๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II double-blind, placebo-controlled randomized trial of an escalating dose of thalidomide in the treatment of Alzheimer's disease: Baseline characteristics

โœ Scribed by Sabbagh, Marwan; Decourt, Boris; Liebsack, Carolyn; Sirrel, Sherye; Walker, Aaron; Gonzales, Amanda; Macias, Mimi; Jacobson, Sandra; Malek-Ahmadi, Michael; Belden, Christine


Book ID
122683416
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
49 KB
Volume
9
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


A double-blind, placebo-controlled singl
โœ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 203 KB ๐Ÿ‘ 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional deยฎcits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire